Related references
Note: Only part of the references are listed.Lopinavir protein binding in HIV-1-infected pregnant women
F. T. Aweeka et al.
HIV MEDICINE (2010)
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms
Ruben C. Hartkoorn et al.
PHARMACOGENETICS AND GENOMICS (2010)
A popluation analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients
Marion Bouillon-Pichault et al.
ANTIVIRAL THERAPY (2009)
Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients
Jean-Fran Ois Delfraissy et al.
AIDS (2008)
Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS french perinatal cohort
Josiane Warszawski et al.
AIDS (2008)
Lopinavir Exposure With an Increased Dose During Pregnancy
Mark Mirochnick et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
Steady-state lopinavir levels in third trimester of pregnancy
Fiona Lyons et al.
AIDS (2007)
The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect
Cheri Enders Klein et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine
Kaveh Manavi et al.
AIDS (2007)
Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV
Qing Ma et al.
PHARMACOGENOMICS (2007)
A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults
Martijn R. van der Leur et al.
THERAPEUTIC DRUG MONITORING (2006)
Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004 - A requirement for therapeutic drug monitoring
Diane T. Holland et al.
THERAPEUTIC DRUG MONITORING (2006)
Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children
J Ananworanich et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2005)
Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography
JAH Droste et al.
THERAPEUTIC DRUG MONITORING (2003)
Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B
SG Lim et al.
GUT (2002)
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results
RL Murphy et al.
AIDS (2001)